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Last year marked the 40th anniversary of the publication
of the first print edition of Mendelian Inheritance in Man
(MIM).1 This seems an appropriate juncture at which to
review its origins, evolution, and present status, including
and particularly those of its online version, OMIM (Online
Mendelian Inheritance in Man). This is an opportunity,
at the same time, to review in brief the rapid progress in
an important part of medical genetics and genomics, as
chronicled in MIM/OMIM over these 40 years, and to con-
template the future challenges of OMIM.
Description of MIM/OMIM
MIM1,2 is a comprehensive knowledgebase of human genes
and genetic disorders. It consists of full-text overviews of
genes and genetic phenotypes, particularly disorders, and
is useful to students, researchers, and clinicians. It was
initiated in the early 1960s as a trilogy of catalogs of
autosomal dominant, autosomal recessive, and X-linked
phenotypes. It has been maintained as an electronic file
since 1964 and has been published in 12 print editions
(fig. 1), the first in 1966, the most recent (in three vol-
umes) in 1998. (Various editions of MIM were translated
into Russian [1976], Spanish [1976], and Mandarin [1996];
see fig. 2.) In 1987, it became generally available on the
Internet, under the designation “OMIM,” from the Welch
Medical Library at Johns Hopkins University. Since De-
cember 1995, it has been distributed on the World Wide
Web from the National Center for Biotechnology Infor-
mation (NCBI) of the National Library of Medicine. This
knowledgebase is updated daily. Authoring and editing
are headquartered at Johns Hopkins University School of
Medicine.
Origins and Evolution of the Structure
and Organization and Content of MIM/OMIM
MIM had its origins in three different endeavors3: first, the
annual reviews of medical genetics that my colleagues and
I in the Moore Clinic at Johns Hopkins prepared for each
of 6 years, 1958–19634,5; second, a catalog of X-linked
traits that I compiled in 1962 as an assessment of the
genetic content of the X chromosome6,7; and, third, a cat-
alog of autosomal recessive phenotypes that I prepared in
1963 as a resource for identifying both “old” and “new”
recessive diseases in studies of the Old Order Amish.8,9
In the original three catalogs corresponding to the three
major modes of Mendelian inheritance, the entries were
arranged alphabetically according to the preferred title of
the particular phenotype, and numbering was done con-
secutively. By the 11th book edition in 1994,2 the X-linked
catalog had been joined by two other chromosome-spe-
cific catalogs: those for the Y chromosome and for the
mitochondrial chromosome. Entries in the original auto-
somal dominant, autosomal recessive, and X-linked cat-
alogs had been assigned unique identification numbers,
beginning with 1, 2, and 3, respectively. Entries in the two
new chromosome-specific catalogs were given uniquenum-
bers beginning with 4 (Y-linked) and 5 (mitochondrial).
(Entries were given 4-digit numbers in the first [1966] and
second [1968] book editions of MIM. Entry numbers were
expanded to 5 digits with the third [1975] edition by add-
ing a zero to the 4-digit numbers of previously existing
entries and to 6 digits in the 9th [1990] edition by the
same method.)
Since May 1994, a distinction between autosomal dom-
inant and autosomal recessive traits has not been main-
tained in MIM. All autosomal traits (or genes) for which
new entries were created were added consecutively to a
new catalog, with 6-digit numbers beginning with 6. No
new entries were added to the original autosomal domi-
nant and autosomal recessive catalogs that had unique
entry numbers beginning with 1 and 2, although copious
new information bearing on previously existing entries in
these original catalogs has been added. (A caveat: some
entries that remain in the catalogs with numbers begin-
ning with 1 or 2 relate to phenotypes not now considered
dominant or recessive, respectively, in the light of newer
understanding.)
The reasons for discontinuing the distinction between
autosomal dominant and autosomal recessive entries in-
cluded the fact that entries were being created for an in-
creasing number of genes for which there was extensive
information, including location on a specific autosome,
but no associated Mendelian phenotypic variation with
either dominant or recessive inheritance. Also, the distinc-
tion is only relative—that is, whether dominant or reces-
sive sometimes depends on the level at which the phe-
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Figure 1. Twelve print editions of MIM, the first published in 1966 and the most recent, in three volumes, published in 1998
Figure 2. Foreign-language editions of MIM: (left to right) Span-
ish (Mexican) edition, translated by Rudolfo Guzma´n Toledano,
1976; Russian edition, translated by E. K. Gentera and V. I. Iva-
nova, 1976; and Mandarin edition, translated by Wilson H. Y. Lo
and others (two volumes), 1996.
notype is analyzed. For example, in several of the red-cell
enzymopathies, the deficiency state is autosomal recessive
but the electrophoretic variation is likely to be demon-
strable in the heterozygote—that is, it is dominant, or at
least intermediate, in its inheritance. Furthermore, there
are rather numerous examples of particular phenotypes
that are inherited as dominant or recessive based on dif-
ferent mutations in the same gene. Table 15 on page l in
the preface of MIM122 listed 11 disorders that have both
dominant and recessive forms resulting from different mu-
tations in the same gene. Some mutations that cause ab-
sent function of the protein—that is, null mutations—
produce phenotypic effects only with homozygosity; mis-
sense mutations may cause the disorder because of a dom-
inant negative effect when, for example, the structure of
a protein that is part of a heteromeric protein complex is
altered.
Starting with the first edition of MIM, two classes of
entries were differentiated. Those for which the particular
mode of inheritance was considered quite certain and the
phenotype was thought to be distinct from any already
represented by an entry were distinguished by an asterisk
(*) preceding the unique entry number. The asterisk was
omitted in the case of entries for which the phenotype
was less certainly Mendelian, less clearly of the particular
mode of inheritance, or not distinct from a phenotype
described in another entry. The inclusion of these un-
asterisked entries was considered important for heuristic
purposes.
From the beginning, the gene behind the phenotype
was always kept in mind. For most of the first 15 years of
the catalogs and more, however, there was little way to
know whether a given phenotype was in fact caused by
mutation in a single gene or might be caused by mutation
in any one of two or more different genes, and it was
usually impossible to tell whether two or more quite dif-
ferent phenotypes were due to mutations in the same
gene. Since 1990, separate entries have been, as a rule,
created for phenotypes and the genes that have mutations
causing those phenotypes.
The practice of separate entries for genes and pheno-
types was initiated, in large part, to handle the issues of
one phenotype–several genes and of one gene–several
phenotypes. Entries describing phenotypes for which the
mutational basis has been found in one or more genes are
flagged with a number sign (#) preceding the unique entry
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Table 1. OMIM Statistics as of January 29, 2007
Entry Classification
No. of Entries by Category
Autosomal X Linked Y Linked Mitochondrial Total
* Gene with known sequence 10,644 495 48 37 11,224
 Gene with known sequence and phenotype 356 32 0 0 388
# Phenotype description, molecular basis known 1,851 169 2 26 2,048
% Mendelian phenotype or locus, molecular basis unknown 1,411 134 4 0 1,550
Other, mainly phenotypes with suspected Mendelian basis 2,014 144 2 0 2,160
Total 16,276 974 56 63 17,370
number, and the initial paragraph indicates the entry num-
ber of the gene(s) in which the mutation(s) is described.
Gene entries have an asterisk preceding the unique num-
ber. Entries that contain both phenotype and gene infor-
mation are flagged with a plus sign (); X-linked examples
include HPRT (MIM 308000), G6PD (MIM 305900),
and HEMA (MIM 306700). Beginning in 2004, other
Mendelizing phenotypes, regardless of whether they have
been mapped, have been denoted by a percent sign (%)
preceding the entry number when the causative gene has
not yet been identified and cloned. Table 1 presents cur-
rent statistics on these several categories of entries.
Beginning with hemoglobinopathies as early as the first
edition (1966) and in full force by 1988 (MIM8), allelic
variants (AVs) (or mutations) have been appended to the
gene entries—for example, the beta-globin gene (HBB) en-
try (MIM 141900). At present, each AV is given a unique
10-digit number, consisting of the primary 6-digit number
for the gene followed by a 4-digit extension beginning
with .0001 for the first listed AV. As of December 4, 2006,
the HBB entry cataloged 537 AVs of the HBB gene, num-
bered MIM 141900.0001 to141900.0537. The entry of
each AV consists of the title of the trait (phenotype) de-
termined by the mutation, the gene symbol and the short-
hand description of the mutation,10–12 text providing a
varying amount of information on the family(ies) or pop-
ulation(s) studied, the details of the specific DNA change,
and peculiarities of phenotype and genetics. “Allelic Var-
iants” was selected as the heading of that section of gene
entries rather than “Mutations” because, together, they
represent an allelic series. Furthermore, the title of each
AV is the phenotype (not the mutation), which, in some
instances, can be an electrophoretic or antigenic poly-
morphism of an enzyme or plasma protein. The molecular
bases of the variation in blood-group antigens are given
as AVs, for example.
Selection of particular mutations of a given gene for
inclusion as AVs in OMIM has been based on general cri-
teria, including the following: (1) the first or first few dis-
ease-related mutations to be identified in the given gene;
(2) any mutation with a particularly high frequency, such
as Phe508del in the CFTR gene (MIM *602421.0001) in
cystic fibrosis (MIM #219700); (3) a mutation related to a
distinct phenotype not previously represented in the list;
(4) mutations of historical interest, such as the specific
mutation in the family or population in which the phe-
notype was first described—for example, the mutation in
the CLCN1 gene (MIM *118425.0006) in the family of
Dr. Thomsen, who first described Thomsen disease (MIM
#160800); (5) any mutation with a peculiar ethnic or geo-
graphic distribution; (6) any mutation arising through a
distinctive mutagenic mechanism such as gene conver-
sion (as in classic congenital adrenal hyperplasia due to
21-hydroxylase deficiency [MIM *201910.0001]) or gene
fusion (as in Hb Lepore [MIM 142000.0019ff]); (7) any
mutation producing the phenotype through a distinctive
pathogenetic mechanism; (8) mutations associated with
autosomal dominant versus autosomal recessive inheri-
tance with different mutations in the same gene, as in
therecessive (MIM *139250.0005) and dominant (MIM
*139250.0007) forms of isolated growth hormone defi-
ciency due to allelic mutations in the growth hormone
gene (GH1); and (9) polymorphisms demonstrating asso-
ciation with disease—for example, the Y402H polymor-
phism of complement factor H (CFH [MIM *134370.0008])
in age-related macular degeneration (MIM #603075). The
last category represents so-called susceptibility genes, as
discussed later. Most are part of the multifactorial basis of
common disorders.
OMIM provides links to comprehensive mutation
listings, including the Human Gene Mutation Database
curated at Cardiff, and many locus-specific mutation da-
tabases (LSDBs)—for example, PAHdb (Phenylalanine Hy-
droxylase Locus Knowledgebase) and CFTRdb (Cystic Fi-
brosis Mutation Database) for PKU and cystic fibrosis
mutations, respectively, as well as the Human Genome
Variation Society based in Melbourne, which maintains
information on 1500 LSDBs.
Evolution of MIM/OMIM from a Catalog
of Mendelian Phenotypes to a Catalog of Human
Genes and Genetic Disorders
The first print edition of MIM in 1966 had the subtitle
Catalogs of Autosomal Dominant, Autosomal Recessive and
X-linked Phenotypes.1 In the 1994 edition,2 the subtitle be-
came A Catalog of Human Genes and Genetic Disorders—a
reflection of the progress in the field since the 1960s.
Nearly all of the 1,486 entries in the first edition of MIM
discussed phenotypes. As of January 29, 2007, 6,146 of
the 117,300 entries in OMIM represented phenotypes (see
table 1 and fig. 3); the rest related to genes. Beginning in
www.ajhg.org The American Journal of Human Genetics Volume 80 April 2007 591
Figure 3. Growth of MIM and OMIM, in terms of total number of
entries.
the late 1960s, entries were created in MIM for individual
genes for which no associated Mendelian phenotype was
known. The method of interspecific (e.g., mouse-human)
somatic cell hybridization made it possible to map genes
to specific human chromosomes without the existence of
a Mendelizing phenotype that could be used in family
linkage studies. The difference between the genomes of
the two species in the hybrid substituted for the differ-
ences between the genomes inherited from father and
mother used in family linkage mapping. Thus, when the
thymidine kinase gene (TK1 [MIM *188300]) was mapped
to chromosome 17 by study of mouse-human hybrid cell
lines,13,14 an entry was created for the gene, even though
no Mendelian variation was known. Already, separate
entries had been created for hemoglobin genes such as
HBB, the lactate dehydrogenase genes such as LDHA (MIM
150000), and the G6PD gene (MIM 305900), among
others. As mapping and cloning of genes advanced, the
genes involved were given new entries in MIM, again al-
though no Mendelian variation may have been known.
Until the generic autosomal catalog was established (in
1994), autosomal “gene entries” were arbitrarily incorpo-
rated in the autosomal dominant catalog.
In the accessioning and curating of gene entries, OMIM
works closely with the NCBI reference sequence project
and the Human Genome Organisation (HUGO) nomen-
clature committee. Because each group is involved in cur-
ating genes and sequence information, a method for shar-
ing each group’s analyses was established under the di-
rection of Donna Maglott at NCBI. This collaborative ef-
fort resulted in the public resource “Locus Link” and its
successor “Entrez Gene.” This initiative allows Alan Scott,
OMIM’s Deputy Scientific Director for Genes, to review
genes in OMIM, to remove duplicates, and to identify
“new” genes for consideration of inclusion in OMIM. This
is a considerable undertaking, since nearly 23,000 genes
with supporting sequence have been identified.
Evolution of MIM/OMIM as an Electronic Resource
MIM has been maintained on computer since early 1964.15
In those pre–word processor days, maintenance on the
mainframe computer was a boon to the updating process
and facilitated preparation of camera copy, including au-
thor and subject indices, for book publication. That ad-
vantage for book publication continued. For example,
from 1986 (MIM7) to 1994 (MIM11), it was possible to
produce a print edition in 4 months at 2-year intervals.
With closing of the files on March 1, bound books would
be available by July 1. A time-consuming task during those
4 months was preparation of the front material (including
the Synopsis of the Human Gene Map) and the indices.
The process of vetting the indices in preparation for the
book was valuable for detection of errors, including du-
plications, misspellings, inconsistent nomenclature, etc.
The book was published by photo-offset of the computer
printout (in all uppercase letters for the first three editions,
1966, 1968, and 1971) and of camera-ready copy prepared
by automatic typesetting in the subsequent editions.
In the 1980s, a new era began, with the adoption of
MIM by the National Library of Medicine as the test bed
for the development of IRx (Information Retrieval Exper-
iment), a method of authoring and editing that permitted
the rapid search of specific text material.16 An online ver-
sion of the 6th edition of MIM (1983) with updates and
with the IRx search engine was demonstrated at the Bar
Harbor Medical Genetics Course in July 1985 and was used
as a resource at the eighth Human Gene Mapping Work-
shop in Helsinki in August 1985. By the fall of 1985, an
online version of MIM, now called “OMIM,” with the IRx
search engine became a major aid in authoring and editing
OMIM. Searchability helped to avoid duplications and in-
consistencies and allowed entries to be related to each
other—cross-referenced—more easily. Beginning in Sep-
tember 1987, OMIM was made generally accessible on the
Internet from the Welch Medical Library of Johns Hopkins
University. The informatics aspects of OMIM were trans-
ferred to the NCBI of the National Library of Medicine on
December 1, 1995. Thus, in the 31 years from 1964 to
1995, MIM went from a solitary resource on magnetic tape
to a cornerstone genetics resource on the World Wide
Web, integrated with other primary genetic data sources.
OMIM was one of the first electronic resources to exploit
the advantages of the Web.
Nosology and Nomenclature in MIM/OMIM
Nosology (literally meaning ”the study of disease” but cus-
tomarily taken to mean the classification or delineation
of disease), nosography (“the description of disease”), and
the nomenclature of disease have necessarily been central
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considerations throughout the history of MIM. Indeed,
nosology and nosography, viewed as the delineation of
distinct genetic traits, are the main bases for assembling
MIM. The basic premise has been that “Mendelization”
indicates that the phenotype represents a distinct disorder
or trait related to a specific mutation in a specific gene
and deserves a specific name. In his monograph entitled
Nosography,17 which was published in 1930, Knut Faber,
Copenhagen professor of medicine, attributed to Mendel
a major, albeit indirect, role in guiding thinking along
lines of specific disease entities with specific etiology (cau-
sation), comparable to the role played by the pioneers
in bacteriology in the late 1800s and early 1900s. Two
hundred years ago, angina pectoris, asthma, consump-
tion, dropsy, jaundice, stroke, and many symptom com-
plexes were viewed and managed as though they were
distinct entities with a single etiology.
Nosology and the related naming of genetic disorders
have both practical and theoretical significance—practical
because of their importance to diagnosis, prognosis, and
management and theoretical because of the implication
that the disorder represents a distinct entity with a distinct
mutational basis. These were important topics of discus-
sion at the five annual conferences on the clinical delin-
eation of birth defects held at the Johns Hopkins Hospital
(1968–1972). (The proceedings of these five conferences
on the Clinical Delineation of Birth Defects were pub-
lished by the March of Dimes in 16 volumes. See, for ex-
ample, the publication on skeletal dysplasias, which were
discussed on the 3rd and 4th days of the first conference
in 1968.18) When a Mendelizing disorder was described in
a single large kindred or in a collection of kindreds, the
question arose as to whether the condition was the same
as a previously described entity or the same in all kindreds
studied. The question brought out debates between “lump-
ers” and “splitters.”19,20 The lumper and splitter contro-
versies have often been resolved only by molecular elu-
cidation at the DNA level. It turned out that both the
lumpers and the splitters were in part correct. Molecular
elucidation revealed numerous instances of “many from
one” (multiple phenotypes from different mutations in
the same gene) and “one from many” (the same pheno-
type from mutations in two or more separate genes).
The main principles of clinical genetics are pleiotrop-
ism, genetic heterogeneity, and variation. Pleiotropism—
multiple phenotypic effects of a single mutant gene, the
basis of syndromes—mandates lumping of disorders that
may have been separately described on the basis of fea-
tures that predominate in one group of patients. Genetic
heterogeneity, however recognized, is a basis for splitting.
Some aspects of variation will be discussed later, in con-
nection with multifactorial inheritance.
With molecular characterization of an increasing num-
ber of genetic disorders through gene mapping followed
by positional cloning, genetic heterogeneity independent
of phenotypic heterogeneity has been recognized as more
frequent than previously realized. When the causative mu-
tations are at different genes/loci, OMIM now considers
the disorders to be distinct entities. See, for example, the
several forms of long QT syndrome: LQT1 (MIM #192500),
LQT2 (MIM152427), LQT3 (MIM #603830), LQT4 (MIM
#600919), LQT5 (MIM 176261), LQT6 (MIM 603796),
and LQT7 (MIM #170390). Often, the phenotype can be
discerned to be somewhat different when the molecular
characterization permits the study of “pure-culture” groups
of cases. Additionally, treatment of the disorder may be
found to be specific to the underlying genetic basis. “Many
from one,” different phenotypes with different mutations
in the same gene, is illustrated by many examples. The
multiple disorders resulting from mutations in HBB, a total
of at least seven, represents an early example. The multiple
disorders resulting from mutations in the lamin A/C gene
(LMNA [MIM *150330])—a total of at least 11, varying
from progeria (MIM #176670) to a form of Charcot-Marie-
Tooth disease (MIM #605588)—provide an impressive re-
cent example.
In general, usage has dictated the choice of the preferred
designations for disorders. The preferred designations
change over time, as popular usage changes; “mucovis-
cidosis” became “cystic fibrosis of the pancreas” and then
simply “cystic fibrosis.” Usage (in the choice of particular
eponyms, for example) tended to vary some between the
United States and Europe, but this is now much less the
case. The preferred designations in OMIM have increas-
ingly been used as a standard in publications, along with
the inclusion of OMIM entry numbers. All alternative des-
ignations of both phenotypes and genes, including his-
torical ones, are usually listed in the heading of each entry.
The initial choice of names for “new” genetic disorders
has been chaotic. In some instances, one feature of a pleio-
tropic syndrome was selected to designate the whole;
examples include arachnodactyly for Marfan syndrome
(MIM #154700) and angiokeratoma for Fabry disease (MIM
#301500). However, often, over time, a constellation of
features was found to be more important to clinical di-
agnosis than was a single feature. Partly for this reason,
eponymic designations have been used heavily and have
much to recommend them. They have the advantage of
conveying no preconceived notion as to the basic nature
of the abnormality. “Hurler syndrome” was, time showed,
a better designation than was “lipochondrodystrophy,”
which Index Medicus continued to use long after the fun-
damental fault was found to concern mucopolysaccha-
rides, not lipid. The eponym is merely a “handle.” Often
the person whose name is used was not the first to describe
the disorder or did not describe the full syndrome as it
subsequently came to be known. Priority disputes I have
never considered important; when it is found that Jones
in fact described a disorder before Smith, it seems pointless
to change from a widely established use of the Smith
eponym.
MIM/OMIM has consistently used the nonpossessive
form of eponyms—for example, “Marfan syndrome,” not
“Marfan’s syndrome.” In this practice, I was schooled by
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J. Earle Moore and others who edited the first edition
(1956) of my “Heritable Disorders of Connective Tissue”21 and
used the then-current edition of the AMA Manual of Style.
Among other advantages, use of the nonpossessive avoids
the mistake of putting an apostrophe in the wrong place,
writing, for example, “Wilm’s tumor” for “Wilms tumor”
and “Grave’s disease” for “Graves disease.”
It has been useful in speech and writing to have acro-
nyms pronounced as single words, for example, TAR syn-
drome (MIM #274000) for thrombocytopenia–absent ra-
dius syndrome, and VATER association (MIM 192350) for
vertebral defects, anal atresia, tracheoesophageal fistula
with esophageal atresia, and radial dysplasia. Initialisms,
such as OFD1 (MIM #311200)–OFD10 (MIM 165590) for
orofaciodigital syndromes, have also been useful. Family
initials, however, as in the Opitz G/BBB syndrome (MIM
#300000), have been abandoned as a method of naming.
Geographic designations are sometimes used—for ex-
ample, familial Mediterranean fever (MIM #249100 and
MIM #134610) and Tangier disease (MIM #205400), but
these can prove a problem when populations outside the
originally described regions are found to have the disease.
In some cases, the nature of the basic defect is used as
the name. Factor VIII deficiency (hemophilia A [MIM
306700]) and G6PD deficiency (MIM #305900) are ex-
amples. In some ways, this has advantages, but the dis-
advantage is indicated by the absence of clinical specific-
ity; there are, for example, a considerable number of dif-
ferent forms of G6PD deficiency, in terms of clinical
presentation.
Pejorative or demeaning designations have always been
discouraged.22–24 They should never be used in the clinic.
“Gargoyle” (or “gargoylism”) for “Hurler syndrome” (MIM
#607014) is a case in point; “bulldog syndrome” (MIM
#312870) is another. Feingold22 appropriately objected
to “bird-headed dwarf” (MIM #210600), “Michelin tire
baby syndrome” (MIM %156610), and “happy puppet
syndrome” (MIM #105830), none of which is a preferred
designation in OMIM. Cohen23 pointed out a possible
problem with gene names in communicating to laymen
the basic nature of the form of holoprosencephaly (HPE3
[MIM #142945]) due to mutations in the “sonic hedge-
hog” gene (SHH [MIM *600725]). Ludman24 stated that he
dreads the day when he will need to counsel a family with
a child with spondylocostal dysostosis (MIM #609813)
caused by mutations in the “lunatic fringe” gene (LFNG
[MIM *602576]). Actually, I doubt that these bizarre
names, which are derived from their homologs in Dro-
sophila, will represent a serious problem. The gene symbol
can be used if that seems preferable.
As referred to earlier, a numbering system has also come
into extensive use in connection with disorders that are
identical or nearly identical but that are due to mutations
in separate genes. In the past decade or so, OMIM has
made increasing use of numerical or alphabetic systems
for phenotypic series (e.g., DFNB#- for the many [168]
forms of autosomal recessive nonsyndromic deafness,
LQT#- for the many [17] forms of long QT syndrome, and
SPG#- for the many [133] forms of spastic paraplegia).
Historically, the precedent for numbering phenotypic
whi series was established with the glycogen-storage dis-
eases, the mucopolysaccharidoses, and the Ehlers-Danlos
syndromes. Confusion can arise when workers use differ-
ent numbers for the same disorder (e.g., see the com-
plementation groups of peroxisomal disorders [MIM
170993ff]) or if the phenotype was not fully character-
ized before being entered into the series.
Nomenclature is important, not only in the designation
of genetic disorders, but also in the naming of genes and
the derivation of appropriate gene symbols.25 Designa-
tions for genes and gene symbols based on those names
have been the responsibility, for 130 years, of the Gene
Nomenclature Committee of the Human Gene Mapping
Workshops held every year or two, beginning in 1973,
and of its successor, the Human Genome Nomenclature
Committee (HGNC) of HUGO, which assumed the re-
sponsibility in 1991.
The naming of the gene and gene product in the case
of “novel” genes found to be mutant in “mystery” dis-
eases, often through mapping followed by positional clon-
ing, has been based in many instances on the name of
the clinical disorder: dystrophin (DMD [MIM #300377])
for the gene product defective in Duchenne muscular dys-
trophy (MIM #310200) was an early example. Huntingtin
(MIM *143100), neurofibromin-1 (MIM *162200) and -2
(MIM *101000), and emerin (MIM *300384) are others.
Connecting Phenes with Genes in MIM/OMIM
Genetics was defined by William Bateson as the science
of biologic variation. It can also be defined simply as the
study of inheritance, and genomics as the study of ge-
nomes.26 However genetics is defined, one of its main ob-
jectives is to identify specific genetic elements underlying
specific phenotypes—to connect phene and gene. The first
of the three original phenotype catalogs, that for the X
chromosome, was published in 19626 as one of three parts
of a review “On the X chromosome of Man.” The catalog
of X-linked traits was assembled as an assessment of the
gene content of the X chromosome. The list of traits, most
of them disorders or diseases, was compared to a photo-
graphic negative from which a positive picture of the ge-
netic constitution of the X chromosome could be derived.
Although the second catalog, that for autosomal recessive
traits, was assembled for utilitarian purposes—that is, as
a resource in the identification of new recessive diseases
in inbred groups such as the Amish—the “gene behind
the phene” was always in mind, and no more than one
entry per gene was wittingly made from the beginning of
MIM in the 1960s. However, in the age before human
molecular genetics, the one gene–several phenotypes and
one phenotype–several genes complexity meant that the
one gene–one entry rule was often on shaky ground.
Connecting phene to gene is particularly important for
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Table 2. Mapping of Clinical Disorders (January 29, 2007)
Mapping Type
No.
Mapped
Loci associated with disorders 3,003
Disorders mapped by association with the gene product 159
Disorders mapped by linkage 942
Disorders “molecularized” 3,345a
Total no. of disorders mapped 4,446
a Number of phenotypes labeled with “(3)” in the Disorder field of
the Synopsis of the Human Gene Map.
Figure 4. Growth of information in MIM concerning mapping of
genes and genetic loci to specific human chromosomes in the
period up to the initiation of the Human Genome (Sequencing)
Project. In 1968, when the first gene was assigned to a specific
autosome (the Duffy blood group to the centromeric region of
chromosome 1),27 MIM recorded 68 X-linked phenotypes with an
asterisk, indicating confidence in X-linked inheritance.
medical genetics, because definition of the precise muta-
tional lesion allows specific diagnosis. Moreover, it sepa-
rates homogeneous clusters of cases for evaluation of prog-
nosis and therapy and for elucidation of the steps from
gene back to phene that can be important to therapy and
prevention.
Mapping the chromosomes—that is, defining the locus
of the genetic elements responsible for particular pheno-
matypes to specific chromosomal sites—was a first step in
connecting phene to gene. The mapping process began
for the autosomes in 196827 and advanced rapidly in the
next 20 years (fig. 4). (In 1968, as indicated by the sec-
ond edition of MIM published that year, 68 phenotypes,
judged to be clearly X linked and therefore honored with
an asterisk, had been mapped to the X chromosome, but
the regional localization on the X chromosome had not
yet been established for any of them.)
As of January 29, 2007, OMIM contained information
about 2,002 genes that had at least one disease-related
mutation. (That count had reached 1,000 by January 1,
2000.28) These 2,002 are the gene entries with at least one
AV. Because many genes have more than one distinct phe-
notype in their mutational repertoire, the total number
of phenotypes that have been tracked to the DNA level
was 3,345 (table 2). (As noted earlier, this count treats the
phenotype as separate if it is caused by a mutation in a
different gene.) Thus, on average, 1.7 phenotypes have
been related to each of the 2,002 genes. Most of this con-
necting of phene with specific gene has occurred in the
past 20 years. Progress during those years was graphed by
Peltonen and McKusick.29 Much of it has been achieved
by gene mapping (chromosomal mapping of the locus for
the phenotype, to be specific), followed by positional clon-
ing of a previously unknown gene or by the positional
candidate-gene approach.
It came as something of a surprise when the complete
sequence of the human genome revealed many fewer
genes, perhaps by a factor of 10, than might be predicted
from the abundance of gene products. That a gene may
be subject to mutations that cause diverse phenotypes has
a cognate phenomenon: a gene may encode a diversity
of gene products through mechanisms of combinatorial
alternative splicing, posttranslational modification, and
other mechanisms. OMIM attempts to include informa-
tion about the mechanism of the divergent pathologic
phenotypes that occur from mutations in a single gene.
The near ultimate in genotype/phenotype correlation is
provided by a few examples in which change in a single
codon of a single gene results in the disorder. The phe-
notype in each case is as stereotypic as the genotype; mu-
tations in other regions of the same gene result in differ-
ent phenotypes. Striking examples include achondropla-
sia (MIM #100800) due to the c.1138GrA (Gly380Arg)
mutation in the FGFR3 gene (MIM *134934.0001), Hutch-
inson-Gilford progeria syndrome (MIM #176670) due to
the c.1824CrT (Gly608Gly) mutation in the LMNA gene
(MIM *150330.0022), and fibrodysplasia ossificans pro-
gressiva (MIM #135100) due to the c.617GrA (Arg206His)
mutation in the ACVR1 gene (MIM *102576.0001). In the
case of achondroplasia, a few cases are due to a different
nucleotide substitution in the same codon: c.1138GrC
(Gly380Arg [MIM *134934.0002]). Similarly, a mutation
in the same codon as is involved in the majority of cases
of progeria has been found in some cases of that disorder:
GrA (Gly608Ser [MIM *150330.0023]).
In ∼70% of cases, Apert syndrome (MIM #101200) is
caused by a c.934CrG (Ser252Trp) mutation in the FGFR2
gene (MIM *176943.0010) and, in rare other cases, by a
mutation in the next adjacent codon, c.937CrG (Pro253-
Arg [MIM *176943.0011]). No phenotypic features distin-
guishing the two genotypic forms were found.30 As cata-
loged in OMIM, the FGFR3, LMNA, and FGFR2 genes are
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also the sites of mutations causing, respectively, 9, 12, and
11 other phenotypically distinct disorders.
A Garrodian Perspective on MIM/OMIM
“The Lessons of Rare Maladies”
In 1956, I dedicated the first edition of my Heritable Dis-
orders of Connective Tissue21 to Archibald Garrod “and to
all who believe, as he did, that the clinical investigation
of hereditary disorders can shed light on normal devel-
opmental and biochemical mechanisms.” (The dedication
was accompanied by a previously unpublished etching of
Garrod in academic garb by T. Binney Gibbs [created in
1922]. This was provided to me by Garrod’s daughter, dis-
tinguished Cambridge University archeologist Dorothy A.
E. Garrod.) The preface of Heritable Disorders of Connective
Tissue reproduced the now-well-known quotation from a
letter written (in Latin) by William Harvey in 1657 that
Garrod included (in translation) in his paper entitled “The
lessons of rare maladies” published in Lancet in 192831:
Nature is nowhere accustomed more openly to display
her secret mysteries than in cases where she shows traces
of her workings apart from the beaten path; nor is there
any better way to advance the proper practice of med-
icine than to give our minds to the discovery of the
usual law of nature by careful investigation of cases of
rarer forms of disease. For it has been found, in almost
all things, that what they contain of useful or applicable
nature is hardly perceived unless we are deprived of
them, or they become deranged in some way.
This Harveian/Garrodian principle has been extensively
documented in the case of rare genetic syndromes. The
many rare disorders cataloged in OMIM are “experiments
of nature” with much to teach about normal biochemical,
developmental, and physiologic mechanisms, and indeed
much has been learned from them, especially in the 20
years since the first “disease gene” identified by positional
cloning was recorded in OMIM.
Increasingly, basic scientists turn to the human for ex-
ploration of the significance of findings in experimental
systems or look for “human models” of phenotypes or
phenomena in Caenorhabditis elegans, Drosophila, mouse,
and other experimental species. The researcher asks, “Has
a defect related to ‘my’ gene or protein been identified in
the human?” OMIM has proved a useful way to find hu-
man models of “disorders” in experimental organisms.
A human-interest story in this connection involves the
late Robert J. Gorlin (1923–2006) and his son Jed B. Gorlin.
Jed cloned the filamin A gene (FLNA [MIM 300017]) in
199032 and mapped it to Xq28 in 1993.33 It was of partic-
ular delight to his father when FLNA was found (by others)
to be the site of mutations underlying frontometaphy-
seal dysplasia (FMD [MIM #305620]), otopalatodigital
syndrome (OPD1 [MIM #311300]), and several other dis-
orders for which the father had provided definitive clinical
descriptions as well as names.
Garrod’s Generalization: Most Diseases Are Related
to Chemical Individuality
The title of Garrod’s landmark report on the first of his
inborn errors of metabolism was “The Incidence of Al-
kaptonuria, a Study in Chemical Individuality.”34 By “in-
cidence,” he meant occurrence, and, in the work, he re-
ferred particularly to the role of parental consanguinity.
In one short work, he identified consanguinity as a prime
factor in the occurrence of rare recessive disorders and
introduced his concept of chemical individuality.
In Inborn Factors in Disease, a monograph published in
1931, Garrod35 generalized his concept of chemical indi-
viduality to encompass all disease, including common dis-
orders. His thinking was rediscovered by Charles Scriver
and Barton Childs, who, in 1989, published a facsimile
edition of the 1931 monograph, with commentary.36 They
pointed out that the substance of Garrod’s thesis is con-
tained in the following summarizing paragraph at the end
of his 1931 “essay”35(p 157):
It might be claimed that what used to be spoken of
as a diathesis is nothing else but chemical individuality.
But to our chemical individualities are due our chemical
merits as well as our chemical shortcomings; and it is
more nearly true to say that the factors which confer
upon us our predispositions to and immunities from
the various mishaps which are spoken of as diseases, are
inherent in our very chemical structure and even in the
molecular groupings which confer upon us our individ-
ualities, and which went to the making of the chromo-
somes from which we sprang.
Largely on the basis of Garrodian thinking, Childs, in
1999,37 developed what he called “a logic of medicine,”
defining logic as a statement of the formal principles un-
derlying a branch of knowledge. From these analyses came
a vision of individualized medicine—a brand of medicine
designed to match the uniqueness of the individual and
encompassing all disease, including common disease. De-
spite its title Mendelian Inheritance in Man, there are reasons
why identifiable genetic factors in all disease including
those that are not strictly Mendelian should be included
in OMIM (see below). These are the common disorders pre-
viously labeled “multifactorial” and now usually termed
“complex traits” (or disorders). The more we know about
classic Mendelian disorders, the more we realize that these
are also complex; see the example of glycerol kinase de-
ficiency (MIM #307030).38 Conversely, Mendelian subty-
pes of common complex disorders have come to light.
Most forms of cancer are clearly multifactorial, in-
deed multigenic. All are fundamentally genetic, based on
changes in the genetic material; for the most part, they
are somatic genetic disorders. Epigenetic changes are also
importantly involved, as discussed below. In many spo-
radic forms of cancer, multiple genes have been identified
as playing a role in initiation, progression, invasion, me-
tastasis, and resistance to therapy. OMIM records these
somatic mutations among AVs. Somatic mutations related
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to prostate cancer (MIM #176807) are recorded for at least
eight genes and, in the case of some of these genes, both
familial and sporadic forms of prostate cancer are repre-
sented. Colorectal cancer (MIM #114500) displays an even
more extensive array of genes involved in familial and/or
sporadic forms.
In several instances, the gene mutant in familial can-
cer syndromes has been found to undergo somatic mu-
tation to cause sporadic cancer of the type featured in the
familial cancer syndrome. The APC gene (MIM 175100)
mutant in adenomatous polyposis coli is importantly in-
volved in sporadic colorectal cancer, and somatic muta-
tions in APC have been found also in sporadic gastric can-
cer (MIM 175100.0010), sporadic hepatoblastoma (MIM
175100.0024), and other sporadic cancers. The VHL gene
(MIM *608537) is mutant in von Hippel-Lindau syndrome
(MIM #193300), which has renal cancer, pheochromocy-
toma, and cerebellar hemangioblastoma as components; it
is implicated also in sporadic cases of these three neo-
plasms. Germline mutations in the TP53 gene (MIM
191170), somatic mutations of which have been iden-
tified in a variety of cancers, are the basis for one form of
the Li-Fraumeni family cancer syndrome (LFS1 [MIM
#151623]) that combines malignancies of a variety of tis-
sue types, most often soft-tissue sarcomas, osteosarcomas,
and breast cancer. (Li-Fraumeni syndrome is genetically
heterogeneous; in addition to the LFS1 form caused by
mutations in TP53, another form, LFS2 [MIM #609265],
is caused by mutations in the CHEK2 gene [MIM *604373],
and a third form, LFS3 [MIM %609266], maps to a locus
on 1q23.)
Extensions on Mendelism in MIM/OMIM
Classically, the determinants of variation are divided into
genetic and environmental (a.k.a. exogenous or nonge-
netic). Random variation, “chance,” is also an important
determinant. A useful demonstration of both genetics and
chance (stochastic variation) in determination of a par-
ticular phenotype is provided by dermatoglyphic patterns
(MIM %125590): presumably, “fingerprints” are different
in every human being, even identical twins. The basic
differences are laid down by the DNA of the individual;
additional differentiation is provided by stochastic differ-
ences in the embryologic development of the finger pads,
even in individuals with a shared genome, identical twins.
(For a discussion of the difference between DNA finger-
print and dermatoglyphic fingerprints and an illustrative
comparison of the two types in a pair of MZ twins, see
the report of the National Research Council on DNA tech-
nology in forensic science.39)
According to the role of genetic factors in pathogenesis,
I and others found it useful in the early stages of the de-
velopment of medical genetics to divide disease, rather
arbitrarily to be sure, into Mendelian, chromosomal, and
multifactorial.40 The arbitrary nature of this classification
does not detract from its usefulness; all classifications are
to some extent artificial. Consistent with the Garrodian
perspective, all genetic variation, including that with only
a contributing role in the multifactorial basis of a complex
trait and perhaps even some chromosomal (genomic) var-
iation, should be cataloged in OMIM.
In the past 20 years, epigenetic variation has become
evident as a fourth major etiopathogenetic class, especially
in cancer.41,42,43
Chromosomal Variation and MIM/OMIM
Chromosomal variations (aberrations) are of interest for
MIM/OMIM for several reasons. These include the role of
specific genes deleted or duplicated in aneuploid states
in determining phenotype; see Down syndrome (MIM
#190685), Wolf-Hirschhorn syndrome (MIM #194190),
cri-du-chat syndrome (MIM #123450), Emanuel syn-
drome (MIM #609029), 22q11.2 deletion syndrome (MIM
#188400), Jacobsen syndrome (MIM #147791), 9q sub-
telomeric deletion syndrome (MIM #610253), and others.
A large interest of MIM/OMIM in chromosomal aber-
rations is in connection with gene mapping. Notable ex-
amples of identification of the chromosomal locus of Men-
delian disorders through finding small interstitial dele-
tions in sporadic cases include retinoblastoma (MIM
180200) on chromosome 13, Duchenne muscular dys-
trophy on Xp, and adenomatous polyposis coli on chro-
mosome 5. In all three cases, it was the cytogenetic clue
that led to isolation of the mutant gene. One of the earliest
examples of deletion mapping was assignment of the ABO
blood group—adenylate kinase—nail-patella syndrome
cluster of gene loci to 9q34 by Ferguson-Smith et al.44
Aniridia (MIM #106210) was mapped to 11p13 by its oc-
currence alone or as part of the Wilms-aniridia-genito-
urinary-mental retardation syndrome (WAGR [MIM
#194072]) in patients with deletions in that region of 11p.
Deletions have also been a clue to linkage of loci.
Schmickel’s concept of contiguous gene–deletion syn-
dromes45 turned on its ear the idea that syndromes are
always based on pleiotropism of a single mutant gene and
are never due to close linkage of two or more genes, each
of which is responsible for individual components of the
syndrome. Notable examples of contiguous gene–deletion
syndromes in addition to the just-mentioned WAGR in-
clude Langer-Giedion syndrome (MIM #150230), Miller-
Dieker lissencephaly syndrome (MIM #247200), and Wil-
liams syndrome (MIM #194050). Molecular cytogenetics
has aided greatly in the elucidation of this topic. In each
of the examples cited, specific genes that are deleted have
been identified.
Reciprocal X-autosome translocations have been im-
portant for finding the chromosomal location of genes
determining X-linked disorders (and the nature of those
genes). Sporadic cases of an X-linked recessive disorder in
a female with such a translocation was sometimes not only
the main or even the only evidence that the gene was on
the X chromosome, but also the breakpoint on X indicated
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the precise location of the gene. In females with an X-
autosome translocation, the derivative X chromosome (the
derivative chromosome with the centromere of the X) is
active in all cells; if the derivative X chromosome were
inactive (lyonized), its autosomal component would like-
wise be inactive, with cell-lethal effects due to autosomal
monosomy. Thus, the normal X chromosome is the in-
active one, and the derivative X—which may have dis-
ruption of the gene at the breakpoint—is the active one.
The breakpoint, therefore, marks the site of the gene
responsible for the disorder in the patient. Duchenne
muscular dystrophy was among the first disorders to be
mapped by this method; table 1 in the preface of MIM12
(1998) tabulated 16 other examples.2
De novo reciprocal autosomal translocations also can
provide information on the chromosomal site of auto-
somal Mendelian disorders or specific autosomal genes.
Single cases of de novo autosome-autosome translocation
are less informative than are single cases of X-autosome
translocation, because either autosome can be the site of
the gene disrupted by the chromosome break, or perhaps
the phenotype may be the result of a fusion gene—for
example, a joining of the promoter region of one gene
and the coding region of the other. The occurrence of two
or more reciprocal translocations that involve the same
chromosome as one of the partners and involve the same
chromosome band establishes the site of the gene of in-
terest. For example, in the case of type II (ankyrin-related)
hereditary spherocytosis (MIM 182900), the disorder was
mapped to 8p by the discovery of a family with an ap-
parently balanced translocation between chromosomes 8
and 1246,47 and another between chromosomes 3 and 848;
in each family, spherocytosis segregated with the balanced
translocation, and the break in 8p was at the same site.
Many sporadic reciprocal translocations of specific types
have been found in particular hematologic malignancies;
125 were listed in table 3 of the preface of MIM12 (1998),
and many more have been described since then49,50; far
fewer reciprocal translocations have been found in solid
tumors. All are sarcomas: Ewing sarcoma results from fu-
sion of the EWS gene (MIM 133450) on chromosome
22 with genes elsewhere in the genome, such as FLI1
(MIM *193067) on chromosome 11 in the translocation
t(11;22)(q23;q12). Other examples are synovial sarcoma
(SSX1 [MIM 312820] and SS18 [MIM *600192]) and
myxoid liposarcoma (FUS [MIM *137070] and CHOP
[MIM 126337]), resulting from translocations t(X;18)
(11.2;q11.2) and t(12;16)(q13.3;p11), respectively. The
PAX3 gene (MIM *606597), which is mutant in Waar-
denburg syndrome (MIM #193500), when fused with
the FKHR gene (MIM *136533) by translocation t(2;13)
(q35;q14), gives rise to alveolar rhabdomyosarcoma (MIM
#268220).
Molecular genetics study of the translocations in
hematologic malignancies, with characterization of the
genes that are fused or disrupted by the process, has con-
tributed information for creation of many new gene en-
tries in OMIM. The record for promiscuity probably goes
to the gene called “MLL” (MIM 159555) for “myeloid/
lymphoid leukemia.” Situated on 11q23, the MLL gene
partners with genes at 15 or more other chromosomal sites
in reciprocal translocation, to result in mixed-lineage
type leukemia—for example, with AF4 (MIM *159557) in
t(4;11)(q21;q23), AF6 (MIM #159551) in t(6;11)(q27;q23),
AF9 (MIM *159558) in t(9;11)(p22;q23), and ENL (MIM
*159556) in t(11;19)(q23;p13).
Inversions can also cause birth defects or neoplasia, ei-
ther by gene disruption produced by the break at one end
or by the bringing together of control elements of one
gene with the coding portion of another. An inversion in
the long arm of chromosome 2 was a clue to the location
of the gene for Waardenburg syndrome type 1. Inversions
and other aberrations involving 16p were the only evi-
dence of the location of the gene mutant in Rubinstein-
Taybi syndrome (MIM #180849).
Several Mendelian disorders are characterized by in-
creased chromosomal breakage occurring spontaneously
or induced by clastogenic agents and appear to be accom-
panied by a predisposition to malignancy. These chromo-
somal breakage syndromes include Fanconi anemia (MIM
#227650), Bloom syndrome (MIM #210900), ataxia-tel-
angiectasia (MIM #208900), Nijmegen breakage syndrome
(MIM #251260), LIG4 syndrome (MIM #606593), and ICF
syndrome (MIM #242860); the molecular defect is known
in each of these disorders. Some of the most striking chro-
mosomal changes, referred to as “heterochromatic splay-
ing” or “heterochromatic repulsion,” occur in Roberts syn-
drome (MIM #268300). This and the SC phocomelia
syndrome (MIM #269000) are caused by mutations in the
ESCO2 gene (MIM *609353), whose gene product is re-
quired for establishment of sister chromatid cohesion dur-
ing the S phase of the cell cycle.
Molecular cytogenetics and molecular genetics in gen-
eral have narrowed the gap between Mendelian genetics
and the classic cytogenetics of clinical disorders. This is
illustrated by the conditions termed “genomic disorders”
by Lupski,51 many of which show Mendelian patterns of
inheritance.
Variation in gene copy number, through gains (dupli-
cations) or losses (deletions) of chromosome segments, is
as extensive and as potentially significant in disease as that
represented by SNPs.52 Variation in gene copy number has
been demonstrated in many neoplasms, including cancer
of breast, prostate, ovary, colon, head and neck, brain, and
pancreas,53 as well as lymphoma and adenocortical cancer.
It has been suggested54 that the extraordinary copy-num-
ber polymorphism of the complement component-4 (C4A
[MIM 120810]) may be related to defense against infec-
tious disease and susceptibility to autoimmune disease.
Similarly, it is thought55 that an increased copy number
of the trypsinogen-1 gene (PRSS1 [MIM 276000]) may
account for some of the families with hereditary pancre-
atitis without a known causative mutation in that gene.
The beta-defensin genes (e.g., MIM *602215), clustered on
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8p2.1, vary in copy number from 2 to 12. Low copy num-
ber is associated with susceptibility to Crohn disease (MIM
#266600). The CCL3L1 gene (MIM *601395), which occurs
in variable copy number (1–10), shows an association
of copy number with susceptibility to HIV/AIDS (MIM
#609423).56 Copy-number variation of the orthologous rat
and human FCGR3B gene (MIM *610665) is a determinant
of susceptibility to immunologically mediated glomerulo-
nephritis; low copy number was found to be associated
with glomerulonephritis in systemic lupus erythematosus
(MIM #152700).57
Gene duplication is a well-known basis of Mendelian
disorders. Most cases of Pelizaeus-Merzbacher disease (MIM
#312080) are caused by duplication of the PLP1 gene (MIM
*300401). In many instances, Charcot-Marie-Tooth dis-
ease type 1a (MIM #118210), another disorder of myeli-
nation, is caused by duplication of the gene encoding pe-
ripheral myelin protein-22 (PMP22 [MIM *601097]). Gene
duplication is sometimes the cause of disease in a small
but nonetheless instructive subsets of patients, including
patients with CHARGE syndrome (MIM #214800) caused
by duplication in the CHD7 gene (MIM *608892),58 pa-
tients with Parkinson disease (MIM #168601) caused by
duplication in the SNCA gene (MIM *163890.0005), and
patients with a form of early-onset Alzheimer disease with
cerebral amyloid angiopathy (MIM #104300) caused by
duplication in the APP gene (MIM *104760.0020).
Twenty-three chromosomal fragile sites are described in
OMIM. Lubs59 discovered the first fragile site, FRAXA, on
Xq (FMR1 [MIM *309550). FRAXA is associated with fragile
X mental retardation syndrome (MIM #300624), the most
common genetic cause of mental retardation after Down
syndrome. A fragile site on chromosome 16q22 (FRA16A
[MIM #136580]) is of historical interest, since it was the
chromosome marker used to confirm the assignment of
the haptoglobin locus (MIM *136580) to chromosome 16
by studies in somatic cell hybrids.60
Multifactorial Disorders (“Complex Traits”)
and MIM/OMIM
Traits in which variation in multiple loci/genes collaborate
with multiple nongenetic (“environmental”) factors, so-
called complex traits, also have their place in MIM/OMIM,
but the way these phenotypes and the underlying genetic
factors are recorded requires special consideration. The
complex traits include all common disorders such as es-
sential hypertension, mental illness, asthma, and so many
more. Some have rare Mendelian subtypes that represent
no problem for entry in OMIM: Lifton and his col-
leagues61,62 tabulated eight rare Mendelian forms of hy-
pertension, each due to a disturbance in the handling of
sodium by the renal tubules.
The demonstration by association or linkage studies of
a relationship between specific variation in a specific gene
and a specific complex disorder has become prominent in
recent years. With these methods, for example, Chang et
al.63 described three blood pressure–related genes on chro-
mosome 1q42. In that study, individual variants in these
three genes accounted for differences of 2–5-mm Hg in
mean systolic blood pressure levels, and the cumulative
effect reached 8–10 mm Hg. Such information on suscep-
tibility (or resistance) genes has been recorded in OMIM
in the entry for the gene (as well as in the entry for the
phenotype) and is represented by an AV under the gene
entry.
Associations with a particular haplotype are recorded
under the phenotype entry if a relationship to a specific
gene is not clear. Some QTLs are recorded as separate en-
tries in MIM/OMIM, their existence demonstrated by link-
age and association studies. These include QTLs for obesity
(e.g., MIM %602025), stature (e.g., MIM %606255), level
of high-density lipoprotein (e.g., MIM %606613), bone
density (e.g., MIM %601884), intelligence (e.g., MIM
%603783), hemoglobin level (e.g., MIM %609319), and
mean telomere length (e.g., MIM %609113).
Oligogenic Inheritance
OMIM describes 114 instances of possible digenic inher-
itance. The first molecular documentation of digenic in-
heritance, reported by Kajiwara et al.,64 concerned retinitis
pigmentosa caused by a heterozygous mutation in the
gene encoding peripherin (RDS [MIM *179605.0004]) in
combination with a heterozygous null mutation in the
unlinked gene (ROM1 [MIM *180721.0001]) encoding rod
outer segment protein-1. Retinitis pigmentosa did not oc-
cur with either mutation alone in the heterozygous state.
Nadeau65 suggested that this is an example of modification
rather than digenic inheritance, ROM1 being the modifier.
He cited classic examples of dominance modification in
mouse models.
Katsanis et al.66 reported several families in which Bar-
det-Biedl syndrome (BBS [MIM #209900]) showed what
they termed “triallelic inheritance”—for example, patients
with BBS who are homozygous for a missense mutation
in the MKKS gene (MIM *604896.0003) and heterozygous
for a mutation in the BBS2 gene (MIM *606151.0013).
Katsanis et al.66 estimated that 40% of patients with BBS-
2 (see MIM #209900) have homozygosity or compound
heterozygosity for mutations in the BBS2 gene in com-
bination with heterozygosity for a third mutation in an-
other BBS gene.
Bartter syndrome type 4 (MIM #602522)—renal salt
wasting and deafness—is most often caused by mutation
in the BSND gene (MIM *606412). In a child with this
disorder whose parents were consanguineous, Schling-
mann et al.67 found no mutation in the BSND gene but
found homozygous deletion of the CLCNKB gene (MIM
*602023.0008) and a homozygous missense mutation of
the linked CLCNKA gene (MIM *602024.0001).
In some cases, the nature of the interaction of the gene
products in a triallelic digenic inheritance pattern can be
deduced—for example, in the case of cortisone reductase
deficiency (MIM #604931) due to an intronic mutation in
www.ajhg.org The American Journal of Human Genetics Volume 80 April 2007 599
HSD11B1 (MIM *600713.0001) and exonic mutations in
H6PD (MIM *138090.0001 –*138090.0002).68 The long QT
syndromes, in which the interaction of mutations in two
different ion-channel genes appear to occur, provide other
examples. OMIM records two examples of the LQT syn-
drome resulting from double heterozygosity for mutations
in two LQT genes—that is, biallelic digenic inheritance.
LQT 1/2 results from heterozygous mutations in the KCNQ1
(MIM *607542.0009) and KCNH2 (MIM 152427.0019)
genes, and LQT3/6 results from heterozygous mutations
in the SCN5A (MIM 600163.0007) and KCNE2 (MIM
603796.0005) genes. LQT 2/5 can result from a hetero-
zygous mutation in the KCNH2 (MIM 152427.0021)
gene and a homozygous mutation in the KCNE1 (MIM
*176261.0005) gene, another example of triallelic digenic
inheritance.
As more is learned about Mendelian disorders, com-
plexities come to light that indicate that most of these
also must be viewed as multifactorial or at least as complex
traits.38 Modifier genes/loci implicated in Mendelian dis-
orders are being identified—for example, the cystic fibrosis
modifier-1 locus (CFM1 [MIM 603855]) in cystic fibrosis.
Imprinting is an important factor contributing to the com-
plexity of inheritance in a number of genetic disorders.
In the instance of the many Mendelian disorders that are
caused by expanded repeats, the random loss and gain in
number of repeats introduce complexities.
Susceptibility Alleles
Susceptibility alleles represent a major part of the OMIM
record of the multifactorial basis of common disorders. In
the case of ∼490 of the ∼2,000 “disease genes” (genes with
one or more disease-related AVs), at least one of the AVs
is a susceptibility (or resistance, protection) allele. Of the
3,345 phenotypes for which the molecular basis is estab-
lished, 375 (11%) are susceptibility phenotypes. By use of
braces or the words “susceptibility to,” these 375 pheno-
types are identified as predisposed to or protected against
in the “Disorder” field of the OMIM Gene Map; a specific
molecular basis is indicated by an appended “(3).”
Many of the susceptibility alleles are common poly-
morphisms, by convention defined as “variations with an
allele frequency of 1.01 (1%).” The relationship of the
polymorphism to the specific disorder has been identi-
fied mainly by association, linkage, and transmission/dis-
equilibrium studies. One of the earliest susceptibility al-
leles to be identified was that related to Alzheimer disease
(MIM #104310), the APOE4 variant of apolipoprotein E
(Cys112Arg [MIM 107741.0016]).69,70
In many cases, more than one common disorder is re-
lated to the same polymorphic allele. In such cases, which
common disorder results is thought to depend on the rest
of the genetic constitution of the individual and particular
environmental circumstances. The different disorders re-
lated to a particular susceptibility allele sometimes have
obvious possible connections, as in the case of different
forms of autoimmune disorders. Even in different indi-
viduals in the same family, the predisposition conveyed
by the susceptibility allele may take the form of different
common disorders. These considerations are the basis
of Becker’s common alleles/multiple common disorders
model of the genetics of common disease.71
Several different types of autoimmune disease (MIM
#109100) have been found to be associated with particular
susceptibility alleles, even in the same family. For exam-
ple, the Arg620Trp polymorphism of the PTPN22 gene
(MIM *600716.0001) has been identified as a susceptibility
allele in insulin-dependent diabetes mellitus, rheumatoid
arthritis, systemic lupus erythematosus, and Hashimoto
thyroiditis. The insertion/deletion polymorphism of an-
giotensin I-converting enzyme (ACE [MIM106180.0001])
has been identified as a susceptibility allele for myocar-
dial infarction, diabetic nephropathy, hemorrhagic stroke,
ischemic stroke, and progression of severe acute respira-
tory syndrome. In addition, the indel polymorphism of
ACE appears to be a QTL for stature. The Val66Met poly-
morphism of the gene encoding brain-derived neuro-
trophic factor (MIM *113505.0002) has been related to
susceptibility to memory impairment, anorexia nervosa,
bulimia nervosa, and bipolar affective disorder, as well as
to protection against obsessive-compulsive disorder and
modification of the age at onset of Parkinson disease.
The common disorders to which susceptibility alleles
have been related include obesity (alleles in 9 different
genes), SLE (in 4), osteoporosis (in 4), osteoarthritis (in 4),
asthma (in 11), myocardial infarction (in 13), coronary
artery disease (5 susceptibility alleles and 1 resistance al-
lele), and hypertension including preeclampsia (in 13).
Susceptibility or resistance alleles have also been identified
for a variety of infections, including tuberculosis, leprosy,
Helicobacter pylori, Legionnaire disease, cerebral malaria,
and, notably, HIV/AIDS. Neuropsychiatric disorders with
identified susceptibility alleles include schizophrenia (in
five genes), various forms of affective disorder (in four),
autism (in five), and obsessive-compulsive disorder (in
two).
Epigenetic Variation in MIM/OMIM
In both the phenotype and the gene entries in MIM/
OMIM, much information is recorded about epigenetic
variation. This is variation in gene expression that is not
encoded in the DNA sequence itself. The many areas of
epigenetics touched on in MIM/OMIM include aspects of
X-chromosome inactivation, autosomal imprinting, the
role of methylation and histone modification, and the
implications for the pattern of inheritance and pheno-
type of Mendelian disorders and for the pathogenesis
of certain developmental abnormalities such as Beck-
with-Wiedemann syndrome (MIM #130650) and many
cancers.
Discussions of X-chromosome inactivation include the
role of specific genes in the creation or maintenance of
the inactive state—for example, XIST (MIM *314670),
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TSIX (MIM *300181), and XCE (MIM *300074). Familial
skewed X inactivation (MIM #300087) is sometimes due
to mutations in the XIST gene; skewed X inactivation oc-
curs also in women heterozygous for some X-linked dis-
orders, including X-linked severe combined immunode-
ficiency (MIM #300400), Wiskott-Aldrich syndrome (MIM
#301000), and dyskeratosis congenita (MIM #305000), in
which cells with the mutation-carrying X chromosomes
are at a selective disadvantage. In such instances, the skew-
ing can be used as a method for diagnosing the hetero-
zygous carrier state. In some instances, skewed inacti-
vation may be a main piece of evidence establishing X-
linked inheritance; for example, Aicardi syndrome (MIM
%304050) is probably X-linked dominant with male le-
thality, to judge from the finding of skewed X inactivation
in females.
Autosomal imprinting is involved in the phenotypic
consequences of uniparental disomy. A prime example is
provided by Prader-Willi syndrome (MIM #176270) in
individuals with maternal uniparental disomy for chro-
mosome 15; since both chromosomes 15 come from the
mother, the individual lacks the paternally expressed gene
IPW (MIM *601491) located in proximal 15q.
The epigenetic silencing of tumor-suppressor genes may
be a more frequent basis for cancer than are point mu-
tations in those genes.43 Aberrant promoter methylation
is associated with loss-of-gene function that can provide
a selective advantage to neoplastic cells, just as do loss-of-
function point mutations. Germline mutations in the VHL
(MIM *608537), BRCA1 (MIM113705), and STK11 (MIM
*602216) genes cause familial forms of renal, breast, and
colon cancers, respectively; the same genes are often epi-
genetically silenced in sporadic forms of these tumors. For
example, the BRCA1 gene is not important only for fa-
milial breast cancer; 10%–15% of women with nonfamilial
breast cancer have tumors in which the BRCA1 gene is
hypermethylated.
Thus, in addition to the 12,000 genes for which one
or more specific disease-related mutations have been
found, other genes cataloged in OMIM are important to
the pathogenesis of cancers through epigenetic mecha-
nisms. These are tumor-suppressor genes silenced through
hypermethylation. Examples include the RASSF1 gene
(MIM *605082) on 3p21, which is often deleted or its pro-
moter hypermethylated in lung cancer. This gene shows
anomalous promoter hypermethylation in a large number
of other tumor types72 as well. As indicated by their names,
other tumor-suppressor genes related to cancers through
epigenetic silencing are “hypermethylated in cancer-1”
(HIC1 [MIM *603825]) on 17p and “hypermethylated in
cancer-2” (HIC2 [MIM *607712]) on 22q.
The converse situation, activation of oncogenes through
hypomethylation, also leads to the development of can-
cers. Indeed, hypomethylation was the first indication of
the role of anomalous promoter methylation in carcino-
genesis, as reported by Feinberg and Vogelstein in 1983.73
Loss of imprinting (LOI), an epigenetic alteration, has
also been found in cancers. LOI of the gene encoding in-
sulinlike growth factor II (IGF2 [MIM 147470]) has been
described for Wilms tumor (MIM #194070), in Beckwith-
Wiedemann syndrome (MIM #130650), and in hepato-
blastoma. LOI of IGF2 is found in normal colonic mucosa
of ∼30% of patients with colorectal cancer (MIM #114500)
but in only ∼10% of normal individuals. In a study of 172
patients in a colonoscopy clinic, Cui et al.74 found that
the adjusted odds ratio for LOI of IGF2 in lymphocytes
was 5.15 for patients with a positive family history, 3.46
for patients with adenomas, and 21.7 for patients with
colorectal cancer. Other work supported the idea that LOI
of IGF2 may be a familial characteristic.
MIM/OMIM as a Historical Document
At the outset in the 1960s, each entry in MIM was assem-
bled and organized like those in the Oxford English Dic-
tionary (OED)75,76; that is, on a chronologic, diachronic
(“through time”), or historical basis, rather than the hi-
erarchic, descriptive, or synchronic (“one point in time”)
method used by textbooks and encyclopedias. After the
initial creation of individual entries, information provided
by new publications was usually added at the end of the
existing record. Even when many entries in MIM reached
a volume requiring reorganization into topical sections,
the diachronic approach was maintained in each section;
thus, the historical development of human genetics and
particularly medical genetics is evident. The line-up of the
12 print editions of MIM (1966–1998) reflects that pro-
gress (fig. 1). The 12 editions are serial cross-sections of
the field over the 33 years, 1966–1998, spaced 3 years
apart, on average.
Progress in human genetics during the 40 years of the
existence of MIM/OMIM can be gauged by several other
measures more meaningful than the size of the books,
including the total number of entries and the number of
entries of particular types. Perhaps the most meaningful
measures of progress are those that relate to the number
of loci/genes mapped to specific chromosomal sites, the
number of genes that have been identified as the site of
disease-related mutations, and the total number of phe-
notypes that have been “molecularized”—that is, found
to be associated with specific DNA mutations. Data on
these three aspects of the scientometrics of human ge-
netics are presented in graphs published elsewhere29 and
in tables 1–3.
In addition to the title and author indices, each of the
12 print editions of MIM contained a foreword/preface
comprising a long essay on Mendelian inheritance, a de-
scription of the methods used in assembling the catalogs,
and a tabulation of statistics on the journals that were
sources of information and on the growth of the catalogs,
in terms of total number of entries. This “front material”
of the book also included a synopsis of the human gene
map and a listing of molecular defects in genetic disorders.
The first synopsis of the human gene map, published in
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Table 3. Molecular Defects in Mendelian Disorders (and Somatic Mutations in
Neoplasms) (January 29, 2007)
Mapping Type
No.
Mapped
Loci in OMIM with at least one known point mutation that causes a disorder or neoplasm 2,002
Mapped disorders for which a causative mutation has been identified 3,345a
Total no. of mutations cataloged in OMIM 14,949
a Number of phenotypes labeled with “(3)” in the Disorder field of the Synopsis of the Human Gene
Map.
the 1971 (3rd) edition, occupied only 1 page; it expanded
to 116 pages in the 1998 (12th) edition. Today, it would
consume at least 256 print pages if presented in the same
format as that used in the 1998 edition.
The Synopsis of the Human Gene Map is available as
an appendix to OMIM on the World Wide Web. It lists,
chromosome by chromosome in tabular form, the genes
mapped to particular sites, beginning at the end of the
short arm. The focus of this map is on the “morbid anat-
omy of the human genome” and is sometimes referred to
as the “Morbid Map.” It is here that relationships between
gene and phene are most easily seen. The Disorder field
in the tabular synopsis of the human gene map lists the
different phenotypes that are due to allelic mutations in
the given gene. An alphabetic listing by disorder, also
available on the Web, shows genetic (locus) heterogeneity, or
how one phenotype can have its basis in mutation in any
one of several different genes/loci. The listing of the genes/
loci by chromosome and the multiple distinct pathologic
phenotypes that are related to mutation in a single gene
best shows phenotypic heterogeneity at a locus.
MIM/OMIM has regularly recorded information on an-
imal models of human disease. The tabular synopsis of
the gene map includes a field for homologous mouse loci,
and, starting with the 8th edition of MIM (1988),1 the
book edition included the Oxford Grid (e.g., p. ccclxi in
MIM12).2 This pictorial representation of human and
mouse homologies was developed by John H. Edwards,
Professor of Genetics at Oxford and Harwell colleagues C.
V. Buckle, A. G. Searle, V. J. Buckle, and others.77,78,79 On
the principle of homology of synteny, the information in
the Oxford Grid often provided an initial clue to the lo-
cation of the homologous gene in the human or provided
support for the chromosomal location identified in the
human. With OMIM on the Web, links can now be made
to several model organism resources, including the Mouse
Genome Database (Mouse Genome Informatics) at The
Jackson Laboratory and Online Mendelian Inheritance
in Animals (OMIA),80 through the Entrez Search and Re-
trieval System of the NCBI.
Use of OMIM in the Clinic and in Research
and Teaching
As a comprehensive account of the state of knowledge of
the genetic basis of health and disease, OMIM is intended
to have wide usefulness to researchers, clinicians, and stu-
dents. OMIM’s aid to the clinician comes particularly in
the area of differential diagnosis and other aspects of the
large number of individually rare Mendelian disorders to
which the human is literally heir. Precise diagnosis is the
basis for quality care and for accurate genetics counseling
and appropriate therapy. It appears that many clinicians
and counselors use OMIM as a reference in patient care.
Information on prognosis, potential complications, and
possibilities for prenatal diagnosis and carrier detection is
important to the care of patients, both by specialists in
medical genetics and by other health professionals who
may rarely encounter these disorders. The diagnostic use-
fulness of OMIM is enhanced by the Clinical Synopsis
section provided with most phenotype entries. Through
NCBI, OMIM is linked to other online clinical resources
such as the highly useful GeneTests, a directory of 1600
laboratories that perform diagnostic testing on 11,300
disorders (November 2006). GeneTests also includes a
large number of frequently revised reviews of various ge-
netic disorders, prepared by clinical experts in a standard-
ized synchronic form, as an aid to clinical and laboratory
diagnosis.
The usefulness of OMIM extends beyond the clinic. Mo-
lecular biologists find OMIM useful for background in-
formation on genes and descriptions of disorders in their
particular areas of research interest. OMIM lends itself well
both to research “mining” and to educational “surfing.”
I have always thought that a great deal can be learned
(and taught) about human genetics, clinical genetics, and
human molecular genetics by means of exercises consist-
ing of questions to which the answers can be found in
OMIM. In 1993, I produced a self-instruction guide and
workbook for use with OMIM.81 An interactive online
workbook might be particularly useful.
Future Challenges of OMIM
As outlined earlier, an objective of OMIM from its begin-
ning as the book MIM has been to catalog the relationship
between phene and gene. The organization of MIM/OMIM
has evolved to accommodate that fundamental objective
of human genetics. Mapping has been important in es-
tablishing that relationship and has been comprehen-
sively chronicled in MIM/OMIM. With completion of the
sequencing of the human genome, all genes have, in ef-
fect, been mapped in terms of their location in the se-
quence, but many remain to be characterized (“anno-
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tated”). The goal now is to relate phenotype to gene
function.
Despite the official completion of the human genome
project several years ago, the number of identified genes
continues to rise, although more slowly. Extrapolating the
growth of the number of genes with “known or inferred
function” suggests that, barring major surprises (such as
the growing number of small RNAs), nearly all genes will
belong to this category in the next 6–8 years. Of course,
“known” is a relative term; we continue to learn new bi-
ology about a great many of the genes already in OMIM.
A challenge for OMIM is to capture information describing
“new” genes while continuing to add important science
to the ∼11,500 current gene entries for which the sequence
is known. Other challenges will be to capture alias gene
names and to register in some orderly way the complexity
of combinatorial alternative splicing and many other sur-
prises that the human genome is likely to reveal.
Mendelian (monogenic or monolocus) phenotypes and
their molecular basis will continue to be the principal fod-
der for the ever enlarging catalogs.82 The mechanism by
which the mutation leads to the phenotype (the steps
from gene to phene) will always be important information
for cataloging. There will be attention also to collation of
information on genetic, epigenetic, and environmental
modifiers of Mendelian phenotypes. A challenge OMIM
already faces is how to catalog complex phenotypes and
complex genotypes and their functional relationships to
each other and to include epigenetics (and epigenomics),
the interaction of genes and gene products, the interaction
with and influence of environment, and the emergent
phenotypes resulting from these interactions—no small
undertaking.
These relationships between complex phenotypes and
complex genotypes are under investigation in a large num-
ber of clinical and epidemiologic research programs, usu-
ally involving, by necessity, large cohorts of subjects, with
use of haplotype data for description of the genotype in
association studies, and covering a range of topics for
study that includes cancer(s), cardiovascular disease(s),
asthma, and mental illnesses. OMIM must continue to
register this information in a manner that is useful to
clinical medicine and that promotes our fundamental un-
derstanding of the genetics of health and disease.
Will there ever be another print edition of MIM? At this
time, that seems unlikely because of the obvious advan-
tages of the electronic version, with its daily updating and
its searchability. The availability of the book in nonelec-
tronic settings and the tables and other appendiceal ma-
terial in the preface and foreword may not justify its ex-
istence. The historian in me regrets the loss of the archival
function of the print edition.
My colleague Alan Scott argues that there would be a
use for a print version of an annotated human genome
atlas with abbreviated MIM entries. He points out that a
book is easier to browse, with opportunities for serendipity
to operate, than is a computerized database. Such an atlas
could be organized chromosome by chromosome with, in
effect, a separate “catalog” for each autosome comparable
to the present chromosome-specific catalogs (X, Y, and
mitochondrial).
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